SLU-PP-332 is a small molecule that activates estrogen-related receptors (ERRα, ERRβ, ERRγ). It emerged from Saint Louis University (hence "SLU") as a research compound studied for mitochondrial biogenesis, fatty acid oxidation, and exercise-mimetic pathway activation in preclinical models.
SLU-PP-332 is a pan-ERR (estrogen-related receptor) agonist developed at Saint Louis University. It activates all three ERR isoforms (α, β, γ) with some selectivity toward ERRα. In preclinical models it has been studied for effects on mitochondrial biogenesis, fatty acid oxidation, muscle endurance, and adiposity. It is not a peptide — it is a small molecule — but is sold alongside peptides because it targets similar research spaces.
Estrogen-related receptors (ERRα, β, γ) are nuclear receptors. Despite the name, they are constitutively active — they don't require estrogen as a ligand. They regulate transcription of genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and muscle metabolism. In preclinical studies, exercise training upregulates ERR activity; ERRs are considered major downstream regulators of exercise-induced metabolic adaptation.
Preclinical research on SLU-PP-332 (Burris et al., published 2023-2024) has reported:
These are rodent model findings. Human effects are unknown and unverified. SLU-PP-332 is classified research-use-only.
SLU-PP-332 is a small organic molecule (not a peptide chain of amino acids). It is included in peptide research catalogs because it shares the research space — metabolic, endurance, and mitochondrial research where peptides like MOTS-c and 5-Amino-1MQ are also studied.
SLU-PP-332 is a small molecule developed at Saint Louis University that activates estrogen-related receptors (ERRα, β, γ). In preclinical research it has been studied for effects on mitochondrial biogenesis, fatty acid oxidation, running endurance, and adiposity in rodent models. It is classified as research-use-only.
"Exercise mimetic" is a research shorthand — it means preclinical treatment produces transcriptomic and metabolic changes resembling exercise-induced adaptation. SLU-PP-332 activates ERRs, which are major downstream mediators of exercise-induced muscle adaptation. In rodent models this produces endurance improvement without training. The human translation is unstudied; the label "exercise mimetic" describes the preclinical transcriptomic profile, not a human effect.
SLU-PP-332 targets ERRs (nuclear receptors controlling mitochondrial gene expression). This is distinct from GLP-1 agonists (incretin signaling), 5-Amino-1MQ (NNMT inhibition, methyl group metabolism), and MOTS-c (mitochondrial-encoded peptide, AMPK). Each occupies a different niche in metabolic research. SLU-PP-332's endurance-focus and oral bioavailability are its distinguishing features.
Yes. SLU-PP-332 is legal to acquire for research purposes in the United States. It is classified research-use-only — not for human consumption. Licensed researchers may acquire it for preclinical research protocols.
SLU-PP-332 is included in our catalog because it targets the same research space as our peptide offerings — metabolic, endurance, mitochondrial research. Many researchers studying peptide metabolic compounds want access to ERR agonist tools for comparative studies. SMART MD applies the same 3-lab verification standard to SLU-PP-332 batches as to peptide batches.
Every batch is verified by three independent U.S. laboratories. HPLC purity analysis and mass spectrometry confirmation apply to small molecules (like SLU-PP-332) as well as peptides. Lot-specific COAs are publicly verifiable at smartmdpeptides.com/verify.
Same verification standard as our peptide catalog.